Protectin D1, an omega-3 derived specialized pro-resolving mediator, prevented abdominal aortic aneurysm progression and rupture in mouse models by enhancing macrophage efferocytosis through GPR37 receptor signaling. Treatment reduced aortic diameter, inflammatory cytokines TNF-α and IL-1β, and matrix metalloproteinase-2 expression while preserving elastin integrity and smooth muscle structure. The mechanism involves macrophages more efficiently clearing apoptotic vascular smooth muscle cells, reducing chronic inflammation that drives aneurysm expansion.
This represents a potentially transformative therapeutic approach for a condition with devastating mortality rates. Abdominal aortic aneurysms affect 4-8% of older adults and rupture carries 80-90% mortality, yet no pharmacological treatments exist beyond surgical repair. The omega-3 connection is particularly intriguing given epidemiological links between fish consumption and reduced cardiovascular events. However, translating these promising preclinical results faces significant hurdles. The specialized lipid mediators like protectin D1 are notoriously unstable and difficult to deliver systemically. Additionally, human aneurysms develop over decades with complex pathophysiology that may not fully recapitulate in acute animal models. While encouraging, this remains early-stage research requiring extensive safety and efficacy validation before clinical application.
